Business Wire

LR Health & Beauty invests in the support of its sales partners

14.5.2019 14:18:00 EEST | Business Wire | Press release

Share

LR Health & Beauty continuously invests in the development of modern sales concepts which enable the partners to successfully set up and expand their businesses. The company has now launched the innovative tool "LR MyOffice" to support sales partners with their work in the digital LR world.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190514005504/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

LR Health & Beauty invests in the support of its sales partners (Photo: Business Wire)

Transparent, simple and compatible with all devices

In cooperation with the American software provider Exigo, the direct sales company from Ahlen was able to take digitalisation to the next level. Thanks to "LR MyOffice" sales partners can get information on all relevant business figures and activities at a glance – the data is updated around the clock. What turnover have I achieved thus far this month? How are my team members developing? Are there persons in my team who soon celebrate their birthday or jubilee, whom I can congratulate? "LR MyOffice" has the answers and works as a personal assistant. "The programme helps LR partners to better understand their business figures and to control their business activities", says Andreas Friesch, CEO and management spokesman of LR. Furthermore, the tool runs on all terminal devices – not only on the PC at home but also on tablets and smartphones.

Clear activity orientation for new partners and professionals

The special feature of "LR MyOffice" is that every partner sees at first glance what he and his team members have to do to reach the next bonus or career level. Thanks to easy application, even novices manage the tool with ease and are able to quickly manage their LR business independently. The tool box enables profs to exploit opportunities with regard to structure and daily routine even more efficiently. "We were very pleased to partner with LR to leverage our technical expertise and platform, to create the new tool for LR's partners", says Ed Jarrin, President of Exigo.

Positive feedback in the prelaunch phase

The prelaunch phase started last February – from 14 May, the tool will be available for all LR sales partners. "From my point of view, 'LR MyOffice' has already proved its worth. The partners who used the tool in the prelaunch phase are simply impressed", says Friesch contently. In the course of the next few months, new functions will be added to the programme.

LR Health & Beauty

Under the motto “More quality for your life“, the LR Group with headquarters in Ahlen/Westphalia produces and markets various health and beauty products in around 28 countries. The range includes care and decorative cosmetics, dietary supplements and perfumes. LR Health & Beauty attaches great importance to the processing of premium raw materials. As most articles are manufactured at the Ahlen site, the company stands for top products "made in Germany". The processing of Aloe Vera has been one of the core competencies of LR Health & Beauty for more than 15 years. Only the valuable inside of the leaf is used for the products. With a volume of 12,000 tonnes of Aloe Vera leafs per year, LR is among the world’s largest manufacturers of Aloe Vera products. In Ahlen, the company has established the most modern Aloe Vera production site for Aloe Vera Drinking Gels in Europe. With 1,100 employees as well as thousands of registered sales partners and customers, LR is one of Europe’s leading direct sales enterprises. LR's strong market position is based above all on a high-quality product range and an attractive bonus and training plan which is unsurpassed in the industry. LR also established the LR Global Kids Fund e. V. which provides efficient and unbureaucratic support for deprived children and their families in many different countries around the world in cooperation with local institutions.

Exigo

Exigo is the leading global technology provider in the direct selling industry. Exigo supports 100 direct selling companies around the world, which include 12 of the 2019 DSN Global Top 100 direct sales companies. Exigo’s global clients operate in over 120 countries, 40 currencies and 30 languages.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

LR Health & Beauty
Almut Kellermeyer
Head of PR / Public Affairs
Tel: +49 2382 7060-114
Email: a.kellermeyer@LRworld.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye